Education
About Us
Working with TipRanks
Follow Us
PolyPid Ltd. (PYPD)
:PYPD
PYPD Stock Chart & Stats
$3.60
-$0.21(-6.71%)
At close: 4:00 PM EST
$3.60
-$0.21(-6.71%)
Day’s Range― - ―
52-Week Range$2.30 - $3.96
Previous CloseN/A
Volume10.68K
Average Volume (3M)77.22K
Market Cap
$62.80M
Enterprise Value$52.24M
Total Cash (Recent Filing)$5.61M
Total Debt (Recent Filing)$11.78M
Price to Earnings (P/E)―
Beta0.06
Next Earnings
Feb 11, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding15,897,201
10 Day Avg. Volume48,560
30 Day Avg. Volume77,220
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)2.34
Price to Sales (P/S)0.00
P/FCF Ratio-0.82
Enterprise Value/Market Cap0.83
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.30
Forecast
1Y Price Target
$11.00Price Target Upside205.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.21
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial StabilityPYPD end the quarter with cash, cash equivalents, and short-term deposits of $18.8M, which the company projects will fund operations well into 2026.
Pipeline ExpansionPolyPid is more than just D-PLEX100, with a drug delivery technology that can translate into a future pipeline of multiple products including its long-acting GLP-1 delivery platform targeting obesity and diabetes.
Regulatory ProgressPYPD reported progress across regulatory, partnering, and operational fronts for D-PLEX100, reiterating a clear path toward NDA submission in early 2026 and following the positive Phase 3 SHIELD II readout earlier this year.
Bears Say
PolyPid News
PYPD FAQ
What was PolyPid Ltd.’s price range in the past 12 months?
PolyPid Ltd. lowest stock price was $2.30 and its highest was $3.96 in the past 12 months.
What is PolyPid Ltd.’s market cap?
PolyPid Ltd.’s market cap is $62.80M.
When is PolyPid Ltd.’s upcoming earnings report date?
PolyPid Ltd.’s upcoming earnings report date is Feb 11, 2026 which is in 72 days.
How were PolyPid Ltd.’s earnings last quarter?
PolyPid Ltd. released its earnings results on Nov 12, 2025. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$0.522 by $0.152.
Is PolyPid Ltd. overvalued?
According to Wall Street analysts PolyPid Ltd.’s price is currently Undervalued.
Does PolyPid Ltd. pay dividends?
PolyPid Ltd. does not currently pay dividends.
What is PolyPid Ltd.’s EPS estimate?
PolyPid Ltd.’s EPS estimate is -0.33.
How many shares outstanding does PolyPid Ltd. have?
PolyPid Ltd. has 15,897,201 shares outstanding.
What happened to PolyPid Ltd.’s price movement after its last earnings report?
PolyPid Ltd. reported an EPS of -$0.37 in its last earnings report, beating expectations of -$0.522. Following the earnings report the stock price went down -0.266%.
Which hedge fund is a major shareholder of PolyPid Ltd.?
Currently, no hedge funds are holding shares in PYPD
PolyPid Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.00 (205.56% Upside)
$11.00 (205.56% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.6%
Last 30 Days ▼ 12.1%
Last 30 Days ▼ 12.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
14.32%
12-Months-Change
Fundamentals
Return on Equity
-390.53%
Trailing 12-Months
Asset Growth
36.99%
Trailing 12-Months
Company Description
PolyPid Ltd.
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
PYPD Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call for PolyPid Ltd.'s third quarter of 2025 highlighted significant progress towards regulatory approval and commercial readiness for DPLEX 100, with strong validation from market studies and reduced financial losses. However, increased administrative and marketing expenses posed challenges. Overall, the positive aspects considerably outweigh the negatives.View all PYPD earnings summariesPYPD Stock 12 Month Forecast
Average Price Target
$11.00
▲(205.56% Upside)
Technical Analysis
Citius Pharmaceuticals
―
SAB Biotherapeutics
―
Liminatus Pharma
―
Tao Synergies
―
Apollomics
―
Ownership Overview
21.60%
Insiders
6.94% Other Institutional Investors
71.46% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---